trans-3,4-Dimethylcyclopentanon | 223425-52-3

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: trans-3,4-Dimethylcyclopentanon
• 英文别名: (3S,4S)-3,4-dimethylcyclopentanone；(3S,4S)-3,4-dimethylcyclopentan-1-one
• CAS: 223425-52-3
• 化学式: C₇H₁₂O
• 分子量: 112.172
• InChiKey: ZMGMYCHEWPVBEL-WDSKDSINSA-N

物化性质

• 沸点：
  154.8±8.0 °C(Predicted)
• 密度：
  0.895±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.3
• 重原子数：
  8
• 可旋转键数：
  0
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.86
• 拓扑面积：
  17.1
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  磷酰基乙酸三乙酯 、 trans-3,4-Dimethylcyclopentanon 在 sodium hydride 作用下， 以 四氢呋喃 为溶剂， 以95%的产率得到(S,S)-(3,4-dimethyl-cyclopentylidene)-acetic acid ethyl ester
  参考文献：
  名称：

  Synthesis and in vivo evaluation of 3,4-disubstituted gababutins

  摘要：

  A range of 3,4-alkylated five-membered ring derivatives of gabapentin were synthesised. One compound (21) had an excellent level of potency against alpha(2)delta and was pro. led in in vivo models of pain and anxiety. (c) 2009 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2009.10.121
• 作为产物：
  描述：

  (+)-3,4-Dimethyl-adipinsaeure 生成 trans-3,4-Dimethylcyclopentanon
  参考文献：
  名称：

  Kato,Y., Chemical and pharmaceutical bulletin, 1966, vol. 14, p. 1438 - 1439

  摘要：

  DOI：

文献信息

• Cyclic ketones, their preparation and their use in the synthesis of amino acids
  申请人：——

  公开号：US20030187296A1

  公开（公告）日：2003-10-02

  A method is provided for making an enantiomerically pure of the formula: in which R and R′ represent C1?C10 alkyl, C2?C10 alkenyl or C3?C10 cycloalkyl and the wedges signify (S)- or (R)-stereochemistry, the substituents in compound (II) being trans. Conjugate addition is carried out between an organometallic nucleophile that provides a group R as defined above and (R)-4-acetoxycyclopent-2-en-1-one, (S)-4-acetoxycyclopent-2-en-1-one or a similar compound in which acetoxy is replaced by another leaving group to give, e.g. in the case of the acetoxy compound, a trans 3,4-disubstituted addition product of formula III or IV; The acetyl group is eliminated from the addition product to give an (R)- or (S)-4-alkyl or 4-alkenyl cyclopent-2-en-1-one the compound of formula is then to be hydrogenated to give a cyclopentanone of formula (I) or conjugate addition of a second organometallic nucleophile that provides a group R′ as defined above to the compound of the above formula may be carried out to give a trans 3,4-disubstituted addition product of formula (II). One of the above compounds may be converted e.g. via an intermediate (XV)-(XVIII) (in which the substituents R and R′ and the wedges have the meanings indicated above) to a gabapentin analogue of one of the formulae shown below: in which the substituents R and R′ and the wedges also have the meanings indicated above. 1 2

  提供一种制备公式的对映纯物质的方法：其中R和R′代表C1-C10烷基、C2-C10烯基或C3-C10环烷基，楔形符号表示(S)-或(R)-立体化学，化合物(II)中的取代基为反式。在有机金属亲核试剂和(R)-4-乙酰氧基环戊-2-烯-1-酮、(S)-4-乙酰氧基环戊-2-烯-1-酮或类似化合物之间进行共轭加成，其中乙酰氧基被另一个离去基取代，例如在乙酰氧基化合物的情况下，得到公式III或IV的反式3,4-二取代加成产物；从加成产物中消除乙酰基，得到(R)-或(S)-4-烷基或4-烯基环戊-2-烯-1-酮，然后将该化合物氢化，得到公式(I)的环戊酮，或者对上述公式的化合物进行第二次有机金属亲核试剂的共轭加成，得到公式(II)的反式3,4-二取代加成产物。上述化合物之一可以通过中间体(XV)-(XVIII)（其中取代基R和R′以及楔形符号具有上述所示的含义）转化为下面所示的公式之一的加巴喷丁类似物：其中取代基R和R′以及楔形符号也具有上述所示的含义。
• Method of treating cartilage damage
  申请人：——

  公开号：US20020072533A1

  公开（公告）日：2002-06-13

  The invention relates to a method of preventing or treating cartilage damage by administering a GABA analog such as, for example, a compound of Formula 1 and pharmaceutically acceptable salts thereof, wherein R 1 is hydrogen or straight or branched lower alkyl, and n is an integer of from 4 to 6.

  该发明涉及通过给予类似GABA的类似物，例如Formula1的化合物及其药学上可接受的盐，来预防或治疗软骨损伤的方法，其中R1是氢或直链或支链低碳烷基，n为4至6的整数。
• Method of treating tinnitus
  申请人：——

  公开号：US20030176504A1

  公开（公告）日：2003-09-18

  The invention relates to a method of treating tinnitus by administering an alpha2delta ligand such as, for example, a compound of Formula 1 and pharmaceutically acceptable salts thereof, wherein R 1 is hydrogen or straight or branched lower alkyl, and n is an integer of from 4 to 6.

  这项发明涉及通过给予α2δ配体治疗耳鸣的方法，例如，给予一种符合化学式1的化合物及其药用盐，其中R1是氢或直链或支链低碳烷基，n为4至6的整数。
• APOPTOSIS INHIBITORS
  申请人：MOCHIDA PHARMACEUTICAL CO., LTD.

  公开号：EP1048640A1

  公开（公告）日：2000-11-02

  Apoptosis inhibitors containing as the active ingredient compounds represented by general formula (I) or salts thereof, wherein W1 represents -O-, -CH2-, etc.; W2 represents -CH2-, etc.; W3 represents -O-, -CH2-, etc.; X represent CH, C-, etc.; and A represents formula (α) wherein W4 represents -O-, -CH2-, etc.; W5 represents -CH2 -, etc.; and W6 represents -O-, CH2 -, etc. These apoptosis inhibitors inhibit apoptosis of WC8 cells induced by Fas ligand. In animal models, they potently inhibit the progress of fulminant hepatitis and relieve alopecia caused by anticancer agents. Because of being highly safe, these apoptosis inhibitors are usable as beneficial drugs.

  含有一般式(I)或其盐所代表的化合物作为活性成分的凋亡抑制剂，其中，W1代表-O-，-CH2-等；W2代表-CH2-等；W3代表-O-，-CH2-等；X代表CH，C-等；A代表公式(α)，其中W4代表-O-，-CH2-等；W5代表-CH2-，等；W6代表-O-，CH2-等。这些凋亡抑制剂能够抑制Fas配体诱导的WC8细胞的凋亡。在动物模型中，它们能够强烈抑制暴发性肝炎的进展并缓解由抗癌药物引起的脱发。由于具有高度的安全性，这些凋亡抑制剂可用作有益的药物。
• [EN] HETEROCYCLIC COMPOUNDS AND METHODS OF USE THEREOF<br/>[FR] COMPOSES HETEROCYCLIQUES ET PROCEDES D'UTILISATION DE CEUX-CI
  申请人：MERCK & CO INC

  公开号：WO2001016121A1

  公开（公告）日：2001-03-08

  In accordance with the present invention, there are provided novel class of heterocyclic compounds and methods of use thereof. Compounds of the invention contain a substituted, unsaturated five, six or seven membered heterocyclic ring that includes at least one nitrogen atom and at least one carbon atom. At a ring position adjacent to a ring nitrogen atom, the heterocyclic ring has at least one substituent which includes a moiety, linked to the heterocyclic ring via an alkylene moiety, an alkynylene moiety or an azo group. Invention compounds are capable of a wide variety of uses including modulating physiological processes by functioning as agonists and antagonists of receptors in the nervous system, as insecticides, and as fungicides. The invention further provides methods of modulating the activity of excitatory amino acid receptors using a specifically defined class of heterocyclic compounds including the novel compounds referred to above. In one embodiment, there are provided methods of modulating metabotropic glutamate receptors. The present invention also discloses methods of treating disease using heterocyclic compounds. The invention further discloses methods of preventing disease conditions related to diseases of the pulmonary system, diseases of the nervous system, diseases of the cardiovascular system, diseases of the gastrointestinal system, diseases of the endocrine system, diseases of the exocrine system, diseases of the skin, cancer and diseases of the ophthalmic system. The invention also discloses pharmaceutically acceptable salt forms of the above-described heterocyclic compounds.

  根据本发明，提供了一类新型的杂环化合物及其使用方法。该发明的化合物包含一个取代的、不饱和的五、六或七元杂环环，其中至少包含一个氮原子和至少一个碳原子。在靠近环氮原子的环位置上，杂环环有至少一个取代基，包括一个官能团，通过烷基官能团、炔基官能团或偶氮基团连接到杂环环上。发明的化合物能够广泛应用，包括通过作为神经系统受体的激动剂和拮抗剂来调节生理过程，作为杀虫剂和杀菌剂。本发明还提供了使用特定定义的杂环化合物类来调节兴奋性氨基酸受体活性的方法，包括上述新型化合物。在一种实施例中，提供了调节代谢性谷氨酸受体的方法。本发明还揭示了使用杂环化合物治疗疾病的方法。本发明还揭示了预防与肺系统疾病、神经系统疾病、心血管系统疾病、胃肠系统疾病、内分泌系统疾病、外分泌系统疾病、皮肤疾病、癌症和眼科系统疾病相关的疾病状态的方法。本发明还揭示了上述杂环化合物的药物可接受的盐形式。

表征谱图